A look at the potential survival benefit of statins in patients with systemic autoimmune rheumatic diseases.
Gregory M. Weiss, MD
One caveat: because several risk estimates reached higher confidence intervals, a clinically meaningful risk cannot be completely ruled out.
Ten evidence-based recommendations for the most commonly prescribed drug for JIA.
Is vitamin D supplementation warranted in patients at risk for rheumatoid arthritis?
A non-pharmacologic treatment may have wide-reaching benefits in AS, ranging from weight management to better spinal mobility.
You can expect to see more bony erosion and enthesiophyte growth in your patients with PsA than in those with isolated psoriasis.
When it comes to inflammatory pathogenesis, obesity and rheumatic and musculoskeletal diseases share common features.
How well does the development of clinical synovitis correlate with initial subclinical inflammation?
Findings from the first report on sex-specific predictors of spinal radiographic progression in ankylosing spondylitis.
What are the implications for the timing of these procedures in younger patients with AS?